9th May 2016 07:46
LONDON (Alliance News) - Drug discovery and development firm Redx Pharma PLC on Monday said it has appointed David Lawrence as a non-executive director.
Lawrence will takeover from Derek Lindsay, who will step down from the board but will continue as Redx's chief operating officer.
Lawrence is a non-executive director of Synpromics Ltd, a synethetic biology company he co-founded, and is the former chief executive of Sentintext Therapeutics, a biotechnology company focused on developing vaccines for enteroviruses.
Redx shares were untraded on Monday, having last traded at 34.38 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
REDX.L